Life Biosciences
StartupUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechDevelops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies. | Develops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies. | lifebiosciences.com |
Events
| Date | Event | ||
|---|---|---|---|
| Jun 9, 2026 | First patient dosed with partial reprogramming therapy ER-100lifebiosciences.com· Milestone· Longevity biotech | Longevity biotech | Milestone |
| Jan 28, 2026 | FDA clears IND for Life Biosciences' reprogramming therapy ER-100lifebiosciences.com· Milestone· Longevity biotech | Longevity biotech | Milestone |
Funding
| Date | Round | Amount | |
|---|---|---|---|
| Apr 8, 2026 | Series D | $80M | lifebiosciences.com |
About
- Source
- lifebiosciences.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Sep 25, 2026
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | Life BiosciencesCompany in Longevity biotech: Joined a field, Develops partial epigenetic reprogramming therapies using OSK factors, led by ER-100 for optic neuropathies. | seed | lifebiosciences.com |
| Sep 25, 2026 | Life BiosciencesCompany: Added | seed | lifebiosciences.com |